News

Nasdaq1mon
Bayer Licenses PRMT5 inhibitor From Suzhou Puhe BioPharma
The companies have collaborated for Suzhou Puhe BioPharma’s oral, small molecule protein arginine N-methyltransferase 5 (PRMT5) inhibitor that selectively targets methylthioadenosine ...
BioWorld1mon
Scinnohub Pharmaceutical patents new PRMT5 inhibitors
Scinnohub Pharmaceutical patents new PRMT5 inhibitors March 24, 2025 New protein arginine N -methyltransferase 5 (PRMT5) inhibitors are detailed in a Scinnohub Pharmaceutical Co. Ltd. patent and ...
Pharmabiz1mon
Bayer, Puhe BioPharma ink global license pact to develop, manufacture and commercialize the MTA-cooperative PRMT5 inhibitor
Bayer and Suzhou Puhe BioPharma Co.,Ltd., a clinical-stage biotechnology company, announced that they have entered into a global license agreement for Puhe BioPharma’s oral, small molecule PRMT5 ...
Hosted on MSN1mon
Bayer Licenses PRMT5 inhibitor From Suzhou Puhe BioPharma
Bayer BAYRY announced a licensing agreement with Suzhou Puhe BioPharma Co., a clinical-stage biotechnology company. Suzhou Puhe BioPharma is focused on the research and development of innovative ...